Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and eczema that significantly affects patients’ quality of life. It is traditionally treated with conventional topical and/or systemic agents. Topicals are usually effective for mild cases but not for moderate to severe disease; topicals may also have suboptimal safety, tolerability, and compliance. Thus, there is significant unmet need for more-efficacious therapies for topical-refractory patients and for those with moderate to severe AD. China’s National Medical Products Administration (NMPA) has approved the targeted therapies Dupixent (Sanofi’s dupilumab), Rinvoq (AbbVie’s upadacitinib), and Cibinqo (Pfizer’s abrocitinib) for moderate to severe AD, and many other targeted therapies are in the pipeline. This report provides a comprehensive analysis of China’s AD patient populations, current disease management, lingering unmet needs, and the clinical and commercial potential of current and emerging drugs.
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with dermatologists and pediatricians.
Epidemiology: Diagnosed prevalence of AD in urban versus rural China; clinically relevant and market-relevant drug-treatable populations.
Forecast: Ten-year, annualized, drug-level sales and patient shares of key AD therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase III/PR: 7 agents; Phase II: 10 agents; coverage of select early-phase products.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.